Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin

Recruiting now · Phase 2

Conditions studied: Cancer (Solid Tumors), Vomiting, Cisplatin, Olanzapine

In brief

A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting

Key facts

Study ID

NCT07699276

Run by

Mahidol University

People needed

95

Starts

2026-02-10

Expected to finish

2027-11-15

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• histologically confirmed solid malignancy
• scheduled for first cycle of cisplatin at dosage of at least 50 mg/m2

You may not qualify if…

• pregnancy
• pelvic or abdominal radiation within 4 weeks
• uncontrolled brain metastasis
• other moderate or high emetic risk chemotherapy on day 2-5
• untreated gut obstruction
• known allergy or severe adverse effect from palonosetron or olanzapine
• AST/ ALT > 2.5x or serum creatinine clearance less than 50 ml/min

Where it is running

• Faculty of Medicine Siriraj Hospital, Mahidol University — Bangkok, Thailand (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.